La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Hologic Gestion

Gestion contrôle des critères 4/4

Le PDG Hologic's est Steve MacMillan, nommé en Dec2013, a un mandat de 10.67 ans. La rémunération annuelle totale est $ 15.56M, composée du salaire de 7.6% et des bonus 92.4%, y compris les actions et options de la société. détient directement 0.99% des actions de la société, d'une valeur de $ 187.76M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 7.7 ans.

Informations clés

Steve MacMillan

Directeur général

US$15.6m

Rémunération totale

Pourcentage du salaire du PDG	7.6%
Durée du mandat du directeur général	10.7yrs
Propriété du PDG	1.0%
Durée moyenne d'occupation des postes de direction	3.5yrs
Durée moyenne du mandat des membres du conseil d'administration	7.7yrs

Mises à jour récentes de la gestion

Recent updates

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Jul 21

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Jun 20

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Jan 03

Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns

Dec 02

Analyse de la rémunération des PDG

Comment la rémunération de Steve MacMillan a-t-elle évolué par rapport aux bénéfices de Hologic?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 29 2024	n/a	n/a	US$702m
Mar 30 2024	n/a	n/a	US$467m
Dec 30 2023	n/a	n/a	US$515m
Sep 30 2023	US$16m	US$1m	US$456m
Jul 01 2023	n/a	n/a	US$484m
Apr 01 2023	n/a	n/a	US$753m
Dec 31 2022	n/a	n/a	US$990m
Sep 24 2022	US$14m	US$1m	US$1b
Jun 25 2022	n/a	n/a	US$2b
Mar 26 2022	n/a	n/a	US$2b
Dec 25 2021	n/a	n/a	US$2b
Sep 25 2021	US$15m	US$1m	US$2b
Jun 26 2021	n/a	n/a	US$2b
Mar 27 2021	n/a	n/a	US$2b
Dec 26 2020	n/a	n/a	US$1b
Sep 26 2020	US$14m	US$1m	US$1b
Jun 27 2020	n/a	n/a	US$497m
Mar 28 2020	n/a	n/a	US$453m
Dec 28 2019	n/a	n/a	US$84m
Sep 28 2019	US$12m	US$1m	-US$204m
Jun 29 2019	n/a	n/a	-US$30m
Mar 30 2019	n/a	n/a	-US$11m
Dec 29 2018	n/a	n/a	-US$419m
Sep 29 2018	US$42m	US$1m	-US$111m
Jun 30 2018	n/a	n/a	-US$79m
Mar 31 2018	n/a	n/a	-US$132m
Dec 30 2017	n/a	n/a	US$1b
Sep 30 2017	US$11m	US$1m	US$756m

Rémunération vs marché: La rémunération totale de Steve ($USD 15.56M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).

Rémunération et revenus: La rémunération de Steve a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Steve MacMillan (60 yo)

10.7yrs

Titularisation

US$15,555,032

Compensation

Mr. Stephen P. MacMillan, also known as Steve, serves as an Independent Chairman of the Board at Illumina, Inc. from June 02, 2023. He has been the Chairman of the Board at Hologic Inc. since June 17, 2015...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Stephen MacMillan	Chairman	10.7yrs	US$15.56m	0.99% $ 187.5m
Karleen Oberton	Chief Financial Officer	6yrs	US$3.93m	0.045% $ 8.5m
Essex Mitchell	Chief Operating Officer	less than a year	US$2.17m	0.00018% $ 34.0k
John Griffin	General Counsel	9.5yrs	US$3.34m	0.046% $ 8.7m
Jan Verstreken	Group President of International	no data	US$3.52m	0.031% $ 5.9m
Paul Malenchini	Chief Information Officer	3.1yrs	pas de données	pas de données
Ryan Simon	Vice President of Investor Relations	no data	pas de données	pas de données
Diana De Walt	Senior Vice President of Global Human Resources	no data	pas de données	pas de données
Monica Berthelot	VP & Chief of Staff	10.6yrs	pas de données	pas de données
Erik Anderson	Division President of Breast & Skeletal Health Solutions	4yrs	pas de données	0.0071% $ 1.3m
Jennifer Schneiders	President of Diagnostics Solutions	1.3yrs	pas de données	0.0027% $ 515.8k
Scott Christensen	Senior Vice President of Global Supply Chain	less than a year	pas de données	pas de données

3.5yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: L'équipe de direction de HOLX est considérée comme expérimentée (ancienneté moyenne 3.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Stephen MacMillan	Chairman	10.7yrs	US$15.56m	0.99% $ 187.5m
Scott Garrett	Independent Director	11.3yrs	US$339.96k	0.018% $ 3.5m
Sally Crawford	Independent Director	16.8yrs	US$374.96k	0.057% $ 10.7m
Stacey Stewart	Independent Director	1.6yrs	US$338.44k	0.000070% $ 13.2k
Ludwig Hantson	Independent Director	5.8yrs	US$319.96k	0.0025% $ 474.3k
Charles Dockendorff	Independent Director	7.3yrs	US$344.96k	0.0066% $ 1.3m
Christiana Stamoulis	Independent Director	12.8yrs	US$319.96k	0.019% $ 3.6m
Amy Wendell	Lead Independent Director	7.7yrs	US$319.96k	0.0076% $ 1.4m
Nanaz Mohtashami	Independent Director	less than a year	US$128.96k	0.00032% $ 60.5k

7.7yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de HOLX sont considérés comme expérimentés (ancienneté moyenne 7.7 ans).

Hologic Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Chairman notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Independent Director notifies of intention to sell stock

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Recent updates

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher